AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10846036 — intervention group
Group type: COMPARATOR
Intervention: Control trial (fat meal, 100 g fat)
Number of subjects: 12
Study 10178487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 0
Study 10178487 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion (EC)
Number of subjects: 0
Study 8348062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinol; specific dosages not mentioned; duration of intervention not specified.
Number of subjects: 0
Study 8348062 — intervention group
Group type: COMPARATOR
Intervention: Placebo; specific details not mentioned.
Number of subjects: 0
Study 8348062 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study 2878747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995, 50 micrograms, twice daily subcutaneous injection
Number of subjects: 6
Study 30373463 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS:START intervention to improve sleep for people living with dementia; details on dosage and duration not specified.
Number of subjects: 0
Study 27274151 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic rinse
Number of subjects: 60
Study 27274151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 60
Study 27274151 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal oral rinse
Number of subjects: 60
Study 25778646 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 0
Study 25778646 — intervention group
Group type: COMPARATOR
Intervention: Control (no levocarnitine)
Number of subjects: 0
Study 22944595 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation (TSF) treatment
Number of subjects: 966
Study 20965928 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin once daily for 12 weeks
Number of subjects: 30
Study 20965928 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study 19469405 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrative anaesthesia (gLA)
Number of subjects: 76
Study 19469405 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (gGA)
Number of subjects: 76
Study 16878210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical CVD bur
Number of subjects: 40
Study 16878210 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical CVD bur
Number of subjects: 40
Study 16878210 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD burs
Number of subjects: 40
Study 16878210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin substrate
Number of subjects: 40
Study 16878210 — intervention group
Group type: COMPARATOR
Intervention: Enamel substrate
Number of subjects: 40
Study 16878210 — intervention group
Group type: COMPARATOR
Intervention: Direction of handpiece motion
Number of subjects: 40
Study 12926056 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication in patients with chronic gastritis (N = 50)
Number of subjects: 95
Study 12926056 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive non-metaplastic gastritis
Number of subjects: 95
Study 12926056 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive intestinal metaplasia
Number of subjects: 95
Study 12926056 — intervention group
Group type: COMPARATOR
Intervention: Intestinal-type adenocarcinoma
Number of subjects: 95
Study 11204965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure tourniquet system (250 mmHg)
Number of subjects: 31
Study 11204965 — intervention group
Group type: COMPARATOR
Intervention: High pressure tourniquet system (350 mmHg)
Number of subjects: 31
Study 8803586 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II B (no spontaneous angina at rest in 48 hours prior to PTCA)
Number of subjects: 188
Study 8803586 — intervention group
Group type: COMPARATOR
Intervention: Group III B (presence of spontaneous angina at rest in 48 hours prior to PTCA)
Number of subjects: 188
Study 1555310 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 1090
Study 1555310 — intervention group
Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 1090
Study 1555310 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 16-25 years
Number of subjects: 1090
Study 1555310 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 1090
Study 1555310 — intervention group
Group type: EXPERIMENTAL
Intervention: Month of operation (May to July)
Number of subjects: 1090
Study 1555310 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of haemostasis, surgical experience, and premedication
Number of subjects: 1090
Study 6425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 6425917 — intervention group
Group type: COMPARATOR
Intervention: Standard tricyclic antidepressants
Number of subjects: 0
Study 30852547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT
Number of subjects: 7585
Study 30852547 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of DAPT for 12 months followed by aspirin monotherapy
Number of subjects: 7585
Study 28884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (n=15)
Number of subjects: 31
Study 28884877 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (n=16)
Number of subjects: 31
Study 26990142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring program
Number of subjects: 60
Study 26990142 — intervention group
Group type: COMPARATOR
Intervention: Routine training with faculty supervision (Control)
Number of subjects: 60
Study 25268306 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC) system for anchoring self-expanding metal stents (SEMS)
Number of subjects: 12
Study 21912876 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Number of subjects: 400
Study 21912876 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic surgery
Number of subjects: 400
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: Lifetime pack-years 0-10
Number of subjects: 1045
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: Lifetime pack-years 10-20
Number of subjects: 1045
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: Lifetime pack-years 20+
Number of subjects: 1045
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: 12+ pack-years before age 30 years
Number of subjects: 1045
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 1045
Study 20052723 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 1045
Study 17693371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket (Damon 2)
Number of subjects: 54
Study 17693371 — intervention group
Group type: COMPARATOR
Intervention: Conventional edgewise appliance (Microarch)
Number of subjects: 54
Study 17693371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 17693371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating group
Number of subjects: 54
Study 16225499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuratel (15 mg/kg/day, q.d.s.)
Number of subjects: 76
Study 16225499 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone (10 mg/kg/day, q.d.s.)
Number of subjects: 76
Study 16225499 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone
Number of subjects: 76
Study 16225499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuratel
Number of subjects: 76
Study 11961630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study 11961630 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 60
Study 10404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 18
Study 10404953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8527292 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0476 20 to 800 mg single oral doses
Number of subjects: 18
Study 8527292 — intervention group
Group type: COMPARATOR
Intervention: 200 mg MK-0476 as a solution
Number of subjects: 18
Study 8527292 — intervention group
Group type: COMPARATOR
Intervention: 200 mg MK-0476 capsules after a standard breakfast
Number of subjects: 18
Study 1526087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/ml) in methyl cellulose gel
Number of subjects: 12
Study 1526087 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 12
Study 1526087 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl cellulose alone)
Number of subjects: 12
Study 3887445 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CLI)
Number of subjects: 23
Study 3887445 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 23
Study 31209097 — intervention group
Group type: EXPERIMENTAL
Intervention: HARPdoc intervention
Number of subjects: 96
Study 31209097 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Awareness Training (Control)
Number of subjects: 96
Study 29321337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher clot burden score (B=0.063; 95% CI, 0.008-0.118)
Number of subjects: 195
Study 29321337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher thrombus attenuation increase (B=0.014; 95% CI, 0.003-0.026)
Number of subjects: 195
Study 29321337 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral score
Number of subjects: 195
Study 29321337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus perviousness scores
Number of subjects: 195
Study 26555592 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pass dissection using a motor-driven linear microkeratome system
Number of subjects: 48
Study 23933474 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Fitness (BF - auditory perception)
Number of subjects: 42
Study 23933474 — intervention group
Group type: EXPERIMENTAL
Intervention: Space Fortress (SF - visuomotor/working memory)
Number of subjects: 42
Study 23933474 — intervention group
Group type: COMPARATOR
Intervention: Rise of Nations (RON - strategic reasoning)
Number of subjects: 42
Study 23080240 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-reducing insole
Number of subjects: 299
Study 23080240 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 299
Study 20090348 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoreversible wound gel containing polyhexanide
Number of subjects: 44
Study 20090348 — intervention group
Group type: COMPARATOR
Intervention: Flammazine (control)
Number of subjects: 44
Study 18362418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive therapy aiming for targets of <120/80 mmHg and <80 mg/dl for blood pressure and LDL-C respectively.
Number of subjects: 500
Study 18362418 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy aiming for blood pressure <140/90 mmHg and LDL-C <100 mg/dl.
Number of subjects: 500
Study 16485520 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) for 21 weeks
Number of subjects: 50
Study 16485520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling (NC)
Number of subjects: 50
Study 16485520 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) + Nutritional Counseling (NC)
Number of subjects: 50
Study 12095184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 18
Study 12095184 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 18
Study 9566821 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal lymphoadenomegaly present
Number of subjects: 86
Study 9566821 — intervention group
Group type: COMPARATOR
Intervention: Abdominal lymphoadenomegaly absent
Number of subjects: 86
Study 9566821 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with abdominal lymphoadenomegaly
Number of subjects: 86
Study 9566821 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HCV RNA
Number of subjects: 86
Study 9566821 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of gamma-globulin
Number of subjects: 86
Study 8154311 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin
Number of subjects: 287
Study 8154311 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 287
Study 3121165 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion with mitomycin C (CHPP‐M)
Number of subjects: 64
Study 31462727 — intervention group
Group type: EXPERIMENTAL
Intervention: Soursop supplementation (2 × 100 g soursop fruit juice per day for 3 months)
Number of subjects: 143
Study 31462727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 143
Study 31462727 — intervention group
Group type: EXPERIMENTAL
Intervention: Soursop supplementation
Number of subjects: 143
Study 29454333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (PVB) with 0.5% bupivacaine, 15 mL
Number of subjects: 53
Study 29454333 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol, loading dose of 1 mg/kg
Number of subjects: 53
Study 26440201 — intervention group
Group type: COMPARATOR
Intervention: Ti implants (4.1 mm diameter)
Number of subjects: 40
Study 26440201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti‐Zr implants (3.3 mm diameter)
Number of subjects: 40
Study 26440201 — intervention group
Group type: COMPARATOR
Intervention: Both Ti and Ti‐Zr implants
Number of subjects: 40
Study 24163236 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth intervention (telephone counselling and home Internet‐enabled digital video recorders)
Number of subjects: 88
Study 24163236 — intervention group
Group type: COMPARATOR
Intervention: Monthly telephone counselling (control)
Number of subjects: 88
Study 24163236 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth intervention
Number of subjects: 88
Study 20946990 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Yoga of Awareness program (gentle poses, meditation, breathing exercises, yoga-based coping instructions, group discussions)
Number of subjects: 53
Study 20946990 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed standard care
Number of subjects: 53
Study 18179556 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 in wound fluids
Number of subjects: 45
Study 18179556 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFalpha in wound fluids
Number of subjects: 45
Study 18179556 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 at cut-off of 125 pg/ml
Number of subjects: 45
Study 18179556 — intervention group
Group type: COMPARATOR
Intervention: CRP and LBP (serological markers)
Number of subjects: 45
Study 16598749 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 451
Study 16598749 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 451
Study 12702979 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole plus lactoferrin for 7 days (group A)
Number of subjects: 150
Study 12702979 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 7 days (group B)
Number of subjects: 150
Study 12702979 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 10 days (group C)
Number of subjects: 150
Study 10924316 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 168
Study 10924316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 9411221 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator
Number of subjects: 1016
Study 9411221 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic-drug therapy (primarily amiodarone)
Number of subjects: 1016
Study 8377779 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-benzo-[alpha]-pyrone (400 mg for six months)
Number of subjects: 52
Study 2439814 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg
Number of subjects: 257
Study 2439814 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 2 mg
Number of subjects: 257
Study 2439814 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 257
Study 2439814 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 257
Study 2439814 — intervention group
Group type: COMPARATOR
Intervention: bopindolol
Number of subjects: 257
Study 2439814 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 257
Study 30425460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using the mini-mental state examination (MMSE) score
Number of subjects: 163
Study 30425460 — intervention group
Group type: COMPARATOR
Intervention: Bottom category of MMSE score
Number of subjects: 163
Study 27773406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 77
Study 27773406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 24880197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning and physical capacity assessed after 13 weeks of CRC supplementation (2.5 g per day of chicken meat extract containing 40% CRC components).
Number of subjects: 56
Study 24880197 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Fitness Test scores after CRC supplementation.
Number of subjects: 56
Study 24880197 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion levels before and after supplementation in the CRC group.
Number of subjects: 56
Study 24880197 — intervention group
Group type: EXPERIMENTAL
Intervention: STMS scores in the CRC group.
Number of subjects: 56
Study 22644963 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% dosed twice daily
Number of subjects: 496
Study 22644963 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 496
Study 20427668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prednisolone (synthetic mixed glucocorticoid/mineralocorticoid agonist)
Number of subjects: 0
Study 20427668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prednisolone
Number of subjects: 0
Study 20427668 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid receptor antagonist pretreatment
Number of subjects: 0
Study 20427668 — intervention group
Group type: COMPARATOR
Intervention: Mineralocorticoid receptor antagonism
Number of subjects: 0
Study 18480556 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 33
Study 18480556 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 33
Study 16162204 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: tacrolimus and sirolimus
Number of subjects: 132
Study 16162204 — intervention group
Group type: COMPARATOR
Intervention: Group B: mycophenolate mofetil (MMF) and sirolimus
Number of subjects: 132
Study 12598380 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (7VPnCV)
Number of subjects: 707
Study 10696418 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (4 mg/kg for 3 days and 25 mg/kg sulfadoxine)
Number of subjects: 40
Study 10696418 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 40
Study 8738856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact and dispersed josamycin Solutab tablet (1,000 mg)
Number of subjects: 36
Study 8738856 — intervention group
Group type: COMPARATOR
Intervention: Josacine reference sachet (1,000 mg)
Number of subjects: 36
Study 1750747 — intervention group
Group type: EXPERIMENTAL
Intervention: Smectite
Number of subjects: 56
Study 1750747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1750747 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 56
Study 7028010 — intervention group
Group type: EXPERIMENTAL
Intervention: Epikeratophakia
Number of subjects: 14
Study 7028010 — intervention group
Group type: COMPARATOR
Intervention: Keratomileusis
Number of subjects: 14
Study 29796601 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO)
Number of subjects: 114
Study 29796601 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study 28211186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 58
Study 28211186 — intervention group
Group type: COMPARATOR
Intervention: Permacol®
Number of subjects: 58
Study 26743119 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 100
Study 26743119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 23370835 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intervention combined with education and supportive care (Asha life [AL])
Number of subjects: 68
Study 23370835 — intervention group
Group type: COMPARATOR
Intervention: Standard protein with usual care (usual care [UC])
Number of subjects: 68
Study 21610516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training Group (ITG)
Number of subjects: 22
Study 21610516 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 22
Study 21610516 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 22
Study 18295277 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 100
Study 18295277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19839170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 50 J/cm2/100 J/cm3 (laser/RF), two passes, three treatment sessions 30 days apart
Number of subjects: 20
Study 19839170 — intervention group
Group type: COMPARATOR
Intervention: Group B: 30 J/cm2/50 J/cm3, three passes, five treatment sessions 15 days apart
Number of subjects: 20
Study 19839170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20